- Conditions
- Tuberculosis
- Interventions
- PA-824
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1081–1104
of 2,407
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
- Interventions
- Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
- Drug
- Lead sponsor
- Mundipharma Research Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
- Conditions
- Mycobacterium Avium Complex
- Interventions
- Azithromycin, Rifabutin/rifampin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at Tyler
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2017
- U.S. locations
- 1
- States / cities
- Tyler, Texas
- Conditions
- Meningococcal Disease
- Interventions
- MenABCWY, Placebo, MenACWY
- Biological · Other
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 8
- States / cities
- Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
- Conditions
- Pneumococcal Immunization, Healthy Volunteers
- Interventions
- PCV21 vaccine, 20vPCV licensed vaccine
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 42 Days to 89 Days
- Enrollment
- 2,195 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
- Conditions
- Clostridium Infections
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 7
- States / cities
- Sacramento, California • Hamden, Connecticut • Boston, Massachusetts + 3 more
- Conditions
- HIV, Hepatitis C, Hepatitis B, Syphilis
- Interventions
- Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only
- Device
- Lead sponsor
- California State University, Long Beach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Pneumococcal Infections, Pneumococcal Vaccines
- Interventions
- V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 1,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile, Pseudomonas Aeruginosa
- Interventions
- Chlorhexidine
- Drug
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Philadelphia, Pennsylvania
- Conditions
- Gonorrhea, Chlamydia
- Interventions
- ACASI
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 15 Years to 21 Years
- Enrollment
- 801 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Tuberculosis
- Interventions
- Isoniazid, Rifapentine
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 2 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Onychomycosis, Tinea Unguium
- Interventions
- Tavaborole 5% Topical Solution
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 72 Months to 203 Months
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 12
- States / cities
- Madera, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Influenza, Pneumonia
- Interventions
- oseltamivir
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky
- Conditions
- Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
- Interventions
- ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
- Device
- Lead sponsor
- American Laboratory Products Company
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 6
- States / cities
- Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
- Conditions
- Tinea Pedis
- Interventions
- 1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C
- Drug
- Lead sponsor
- Propedix, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Framingham, Massachusetts • Milford, Massachusetts
- Conditions
- Onychomycosis of Toenails
- Interventions
- SKX-16 (Luliconazole 10% Solution), Vehicle solution
- Drug
- Lead sponsor
- SATO Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary
- Interventions
- TBI-223 1800 mg, TBI-223 2400mg, TBI-223 Placebo
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Pneumonia
- Interventions
- PCV7, Prevnar®, Pneumovax 23
- Biological
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 70 Years to 79 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Hiv, Chlamydia, Gonorrhea, Relation, Interpersonal
- Interventions
- 2GETHER, Positive Affect Enhancement
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 256 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Drug Use, Opioid-use Disorder
- Interventions
- Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
- Drug
- Lead sponsor
- Laura Fanucchi
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Meningococcal Infections
- Interventions
- Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
- Biological
- Lead sponsor
- UCSF Benioff Children's Hospital Oakland
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Oakland, California • Worcester, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- NasoShield, Placebo
- Biological · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Meningococcal Infection, Group B
- Interventions
- 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- HIV Infections
- Interventions
- Globulin, Immune, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 48
- States / cities
- Downey, California • Long Beach, California • Los Angeles, California + 29 more